Wen Wee Ma, MBBS, discusses first-line treatment considerations in metastatic pancreatic cancer.
Wen Wee Ma, MBBS, Professor of Oncology, Consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses first-line treatment considerations in metastatic pancreatic cancer.
Currently, the first-line treatment options for patients with metastatic pancreatic cancer consist of FOLFIRINOX or gemcitabine plus nab-paclitaxel (Abraxane), explains Ma. Although both regimens have been approved by the FDA on the basis of pivotal clinical trials, they have yet to be directly compared, Ma says.
As such, treatment considerations are necessary in determining which patients should receive which regimen, Ma adds. A patient’s fitness level and age should be taken into account when selecting treatment, Ma says. The population of the clinical trial which led to the approval of FOLFIRINOX by the FDA included patients under 75 years of age; However, clinical experience has been gained with the use of FOLFIRINOX in patients over 75 years of age who are in solid health, explains Ma.
Ultimately, the choice of treatment should be a shared decision between provider and patient, Ma says. For example, some patients may choose to receive gemcitabine / nab-paclitaxel over FOLFIRINOX because of the potential effects that FOLFIRINOX has. could have on their quality of life, concludes Ma.